Brian J Caveney Form 4 LABCORP / Brian J Caveney ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Caveney Brian J

(Last) (First) (Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON NC 27215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
EVP, Pres of ED, CMO & CSO

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2025		M		670	A	(1)	28,763.6573(2)	D
Common Stock	02/06/2025		F(3)		212	D	$247.74	28,551.6573	D
Common Stock	02/07/2025		M		517	A	(1)	29,068.6573	D
Common Stock	02/07/2025		F(3)		149	D	$246.27	28,919.6573	D
Common Stock	02/07/2025		M		112	A	(1)	29,031.6573	D
Common Stock	02/07/2025		F(3)		33	D	$246.27	28,998.6573	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/06/2025		M			670	(4)	(4)	Common Stock	670	$0	3,070(5)	D
Restricted Stock Unit	(1)	02/07/2025		M			517	(6)	(6)	Common Stock	517	$0	2,553(5)	D
Restricted Stock Unit	(1)	02/07/2025		M			112	(6)	(6)	Common Stock	112	$0	2,441(5)	D

Explanation of Responses:

1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. ("LHI") Common Stock.

2. Amount includes 93.8655 shares acquired on June 30, 2024 and 16.6340 shares acquired on December 31, 2024 under the Labcorp Holdings Inc. Amended and Restated 2016 Employee Stock Purchase Plan.

3. Stock withholding to satisfy tax withholding obligations.

4. The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 6, 2025.

5. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

6. The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 7, 2024.

Remarks:

On May 17, 2024, LHI became the successor of Laboratory Corporation of America Holdings ("LCAH") pursuant to LCAH's reorganization into a new holding company structure (the "Reorganization"). The Reorganization resulted in LHI becoming a parent holding company of LCAH but did not alter the proportionate interests of LCAH security holders.

	/s/ Sandra D. van der Vaart, Attorney-in-Fact for Brian J. Caveney	02/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.